COPENHAGEN: Denmark’s Novo Nordisk on Monday mentioned it has agreed to purchase Cardior Prescribed drugs for as much as 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.
The acquisition is in keeping with the Danish drugmaker’s goal to develop its deal with diabetes and weight-loss therapies to incorporate heart problems therapies.
“By welcoming Cardior as part of Novo Nordisk, we are going to strengthen our pipeline of initiatives in heart problems the place we have already got ongoing programmes throughout all phases of scientific improvement,” Novo mentioned in a press release.
The deal contains Cardior’s lead compound CDR132L, at present in section 2 scientific improvement for the remedy of coronary heart failure, Novo mentioned.
The transaction worth contains an upfront fee and extra funds if sure improvement and industrial milestones are achieved, the corporate mentioned, including it could fund the acquisition from monetary reserves.
The acquisition is in keeping with the Danish drugmaker’s goal to develop its deal with diabetes and weight-loss therapies to incorporate heart problems therapies.
“By welcoming Cardior as part of Novo Nordisk, we are going to strengthen our pipeline of initiatives in heart problems the place we have already got ongoing programmes throughout all phases of scientific improvement,” Novo mentioned in a press release.
The deal contains Cardior’s lead compound CDR132L, at present in section 2 scientific improvement for the remedy of coronary heart failure, Novo mentioned.
The transaction worth contains an upfront fee and extra funds if sure improvement and industrial milestones are achieved, the corporate mentioned, including it could fund the acquisition from monetary reserves.
